CD274 and non-small cell lung carcinoma: First-line treatment with programmed cell death protein-1 or programmed death-ligand 1 (PD-L1) inhibitors, as monotherapy or combined with chemotherapy, represents the standard treatment for patients with advanced NSCLC without target alterations.